Maridebart cafraglutide vs Retatrutide
Compare modality and evidence: long-acting antibody-peptide GLP-1 agonist/GIPR antagonist versus weekly tri-agonist peptide; cross-trial weight percentages cannot establish superiority.
| Attribute | Maridebart cafraglutide | Retatrutide |
|---|---|---|
| Human evidence | Published Phase 1 and randomized Phase 2 evidence show substantial weight-loss signals, and multiple MARITIME Phase 3 programmes are now underway. MariTide remains investigational. | Retatrutide now has peer-reviewed Phase III human evidence in type 2 diabetes (TRANSCEND-T2D-1), alongside earlier randomized Phase II obesity and MASLD data. Obesity Phase III results are also emerging, but published and sponsor-reported evidence should be kept distinct. |
| Research focus | Obesity, type 2 diabetes, cardiovascular outcomes | Obesity, weight management, metabolic disease |
| Regulatory status | Investigational; Phase 3 chronic-weight-management and cardiovascular studies are underway. No marketing authorisation identified. | Not FDA-approved as of this review; FDA states retatrutide has not been found safe and effective for any condition and cannot be used in US compounding. |
| Route / formulation | Maridebart cafraglutide is a long-acting antibody-peptide conjugate, not a conventional peptide vial. | Evidence applies to trial-grade retatrutide, not to unverified research-market vials or pens. |
Why these are compared
These compounds appear in the weight & body composition / emerging agents evidence landscape, but they are not interchangeable. Maridebart cafraglutide is long-acting antibody–peptide conjugate: glp-1 receptor agonist / gip receptor antagonist studied in obesity, type 2 diabetes, cardiovascular outcomes; Retatrutide is tri-agonist peptide (gip/glp-1/glucagon receptor agonist) studied in obesity, weight management, metabolic disease. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Maridebart cafraglutide: Published Phase II evidence; Phase 3 development underway / investigational.
Retatrutide: Multiple Phase 3 human trials; investigational.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No direct head-to-head trial identified. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.